QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NASDAQ:EPIX

ESSA Pharma - EPIX Stock Forecast, Price & News

$2.97
-0.08 (-2.62%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.73
▼
$3.17
50-Day Range
$2.57
▼
$3.55
52-Week Range
$1.40
▼
$8.03
Volume
106,722 shs
Average Volume
236,113 shs
Market Capitalization
$130.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.50

ESSA Pharma MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
522.9% Upside
$18.50 Price Target
Short Interest
Healthy
1.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.84) to ($1.16) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Medical Sector

944th out of 983 stocks

Pharmaceutical Preparations Industry

460th out of 478 stocks

See Top Rated MarketRank™ Stocks Here

EPIX stock logo

About ESSA Pharma (NASDAQ:EPIX) Stock

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Stock News Headlines

March 8, 2023 | finance.yahoo.com
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023 | finance.yahoo.com
ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures
March 22, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
February 23, 2023 | finance.yahoo.com
EPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide…
February 7, 2023 | finance.yahoo.com
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022
February 2, 2023 | finance.yahoo.com
ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference
January 25, 2023 | finance.yahoo.com
A Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)
December 15, 2022 | finance.yahoo.com
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate
March 22, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
December 13, 2022 | msn.com
ESSA Pharma GAAP EPS of -$0.14
December 13, 2022 | finance.yahoo.com
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022
November 15, 2022 | finance.yahoo.com
EPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide…
November 10, 2022 | finance.yahoo.com
ESSA Pharma to Participate in Two Upcoming Investor Conferences
October 31, 2022 | finance.yahoo.com
J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment
October 31, 2022 | finance.yahoo.com
ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials
October 26, 2022 | barrons.com
(PR) ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
October 26, 2022 | finance.yahoo.com
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
September 21, 2022 | finance.yahoo.com
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
September 6, 2022 | reuters.com
ESSA Pharma Inc
August 25, 2022 | seekingalpha.com
ESSA Pharma Inc.: Selling For Under Cash Value
August 16, 2022 | benzinga.com
Multiple Ongoing Studies of EPI-7386
August 4, 2022 | finance.yahoo.com
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022
July 21, 2022 | nasdaq.com
EPIX Stock Gains 11.6% on Insider Buys
July 11, 2022 | finance.yahoo.com
EPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386…
June 30, 2022 | finance.yahoo.com
ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
June 27, 2022 | finance.yahoo.com
ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development
June 2, 2022 | finance.yahoo.com
ESSA Pharma to Present at 2022 Jefferies Healthcare Conference
See More Headlines
Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Company Calendar

Last Earnings
2/07/2023
Today
3/22/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
9/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPIX
CUSIP
N/A
CIK
1633932
Web
www.essapharma.com
Phone
778-331-0962
Fax
604-738-4080
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+514.6%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.74)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,100,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-19.28%
Return on Assets
-18.91%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
56.08
Quick Ratio
56.08

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.79 per share
Price / Book
0.79

Miscellaneous

Outstanding Shares
44,090,000
Free Float
38,801,000
Market Cap
$132.71 million
Optionable
Not Optionable
Beta
2.10

Key Executives

  • Dr. David Ross Parkinson M.D. (Age 73)
    Pres, CEO & Director
    Comp: $829.56k
  • Mr. David S. Wood C.M.A. (Age 66)
    CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer
    Comp: $532.35k
  • Mr. Peter A. Virsik M.B.A. (Age 52)
    M.S., Exec. VP & COO
    Comp: $646.75k
  • Dr. Alessandra Cesano M.D. (Age 63)
    Ph.D., Chief Medical Officer
    Comp: $620.81k
  • Chandtip Chandhasin
    Exec.
  • Erica Osbourne
    Exec.
  • Erin Rudsinski
    Exec.
  • Loleta Harris
    Exec.
  • Neil Thapar
    Exec.
  • Nkengyal Barber
    Exec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













EPIX Stock - Frequently Asked Questions

What is ESSA Pharma's stock price forecast for 2023?

0 analysts have issued twelve-month price targets for ESSA Pharma's shares. Their EPIX share price forecasts range from $17.00 to $20.00. On average, they anticipate the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 514.6% from the stock's current price.
View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts.

How have EPIX shares performed in 2023?

ESSA Pharma's stock was trading at $2.52 at the beginning of the year. Since then, EPIX stock has increased by 19.4% and is now trading at $3.01.
View the best growth stocks for 2023 here.

Are investors shorting ESSA Pharma?

ESSA Pharma saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 236,800 shares, an increase of 17.0% from the February 13th total of 202,400 shares. Based on an average daily volume of 240,400 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.3% of the shares of the stock are sold short.
View ESSA Pharma's Short Interest.

When is ESSA Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our EPIX earnings forecast.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) released its earnings results on Tuesday, February, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.09.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX).

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Soleus Capital Management L.P. (8.78%), Morgan Stanley (4.55%), Avidity Partners Management LP (4.21%), Frazier Life Sciences Management L.P. (1.37%), Driehaus Capital Management LLC (0.60%) and Millennium Management LLC (0.40%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech.
View institutional ownership trends.

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $3.01.

How much money does ESSA Pharma make?

ESSA Pharma (NASDAQ:EPIX) has a market capitalization of $132.71 million. The company earns $-35,100,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The official website for the company is www.essapharma.com. The company can be reached via phone at 778-331-0962, via email at alada@troutgroup.com, or via fax at 604-738-4080.

This page (NASDAQ:EPIX) was last updated on 3/22/2023 by MarketBeat.com Staff